Ownership and insider activity for Abeona Therapeutics Inc. (ABEO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa.
Price
| Price | $5.37 |
| Market Cap | $306M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $69.1M | $137.8M | $18.8M | $129.3M | $12.6M | $32.9M | $14.2M | $14.5M | $23.4M | $78.4M |
| Short-term Investments | 0 | 0 | $66.2M | 0 | $82.4M | $12.1M | $37.9M | $37.8M | $74.4M | $113.0M |
| Receivables | $124000 | $107000 | $81000 | 0 | 0 | $3.0M | $188000 | $2.4M | $1.7M | $6.7M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $5.5M |
| Total Current Assets | $69.4M | $140.6M | $88.9M | $132.4M | $97.7M | $56.3M | $53.1M | $55.7M | $100.9M | $204.9M |
| Property, Plant & Equipment | $721000 | $1.4M | $9.4M | $21.2M | $18.4M | $21.7M | $11.1M | $8.0M | $8.0M | $13.9M |
| Goodwill | $32.5M | $32.5M | $32.5M | $32.5M | $32.5M | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $8.4M | $4.0M | $43.0M | $36.2M | $1.5M | $1.4M | 0 | 0 | 0 | 0 |
| Total Assets | $111.1M | $178.8M | $174.4M | $223.4M | $151.2M | $79.6M | $64.2M | $64.0M | $108.9M | $219.6M |
| Accounts Payable | $3.7M | $1.9M | $6.1M | $3.8M | $4.7M | $4.3M | $1.8M | $1.9M | $3.4M | $7.9M |
| Short-term Debt | 0 | 0 | $10.0M | 0 | $330000 | 0 | 0 | 0 | $5.9M | $12.2M |
| Total Current Liabilities | $8.3M | $5.6M | $20.4M | $38.7M | $42.0M | $16.6M | $7.8M | $13.4M | $16.6M | $29.6M |
| Long-term Debt | 0 | 0 | $20.0M | 0 | $1.4M | 0 | 0 | 0 | $13.0M | $7.8M |
| Total Liabilities | $12.0M | $8.7M | $40.4M | $45.0M | $48.6M | $37.2M | $37.5M | $49.2M | $64.9M | $60.4M |
| Retained Earnings | -$332.5M | -$359.8M | -$410.2M | -$486.5M | -$570.7M | -$655.6M | -$695.3M | -$749.5M | -$813.3M | -$742.1M |
| Total Equity | $99.1M | $170.1M | $134.0M | $178.4M | $102.6M | $42.4M | $26.8M | $14.8M | $44.0M | $159.2M |
| Total Debt | 0 | 0 | $30.0M | $8.0M | $8.7M | $9.4M | $7.6M | $5.4M | $23.0M | $25.0M |
| Net Debt | -$69.1M | -$137.8M | -$55.0M | -$121.3M | -$86.3M | -$35.6M | -$44.5M | -$46.8M | -$74.7M | -$166.4M |
| Working Capital | $61.1M | $135.0M | $68.5M | $93.7M | $55.8M | $39.7M | $45.3M | $42.3M | $84.3M | $175.3M |
Financial Health
| Debt / Equity | 0.16 |
| Current Ratio | 6.63 |
Profitability
| Return on Equity | -41.69% |
| Return on Invested Capital | -39.66% |
| Return on Assets | -35.03% |
| Gross Margin | 56.63% |
| Operating Margin | -327.64% |
| Net Margin | -246.42% |
Related companies: ARCT · ASMB · ELDN · FHTX · HUMA · PBYI · SGMT
Explore sector: Healthcare · Biotechnology
More sections of ABEO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks